1Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension, 1995,25:227-234.
2Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail, 1998,4:37-44.
3Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide ( human B-type natriuretic peptide)in heart failure: a randomized, double-blind, placebo-controlled clinical trial Natrecor Study Group. J Am Coil Cardiol, 1999,34:155-162.
4Silver MA, Horton DP, Ghali JK, et aL Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol, 2002,39 :798-803.
5Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide,a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Meal, 2000,343:246-253.
6Emerman CL Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Bey Cardiovasc Med, 2002,3 Suppl 4 :S28 -S34.
7Peacock WF, Emerman CE, Doleh M, et al. The incidence of non-ST segment elevation MI in emergency department patients presenting with decompensated heart failure. Congest Heart Fail, 2003,9:303-308.
8Peacock WF 4th, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. J Card Fail, 2004,10 : 120-125.
9Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med, 2005,23:327-331.
10Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol, 1999, 276(3 Pt 2) :H1049-H1057.
